Promising study results further strengthen Follicum’s new diabetes drug class patent application
Lund, Sweden, May 14, 2018: Follicum AB (“Follicum” or “the Company”) today announce that the company’s diabetes project is progressing as planned and the company has submitted an enhanced patent application for its novel peptide drug candidate class. A large amount of results have been processed to complete the application submitted in early May 2017. The results are unequivocally positive and show that the new peptide class has the potential to become a valuable addition to the current treatment of diabetes.Follicum initially identified a new class of peptides that increase insulin